The DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index.
Has the era of untreatable infections arrived?
Abstract
Antibiotic resistance is a major public health concern, with fears expressed that we shortly will run out of antibiotics. In reality, the picture is more mixed, improving against some pathogens but worsening against others. Against methicillin-resistant Staphylococcus aureus (MRSA)--the highest profile pathogen--the range of treatment options is expanding, with daptomycin, linezolid and tigecycline all launched, and telavancin, ceftobiprole, ceftaroline and dalbavancin anticipated. There is a greater problem with enterococci, especially if, as in endocarditis, bactericidal activity is needed and the isolate has high-level aminoglycoside resistance; nevertheless, daptomycin, telavancin and razupenem all offer cidal potential. Against Enterobacteriaceae, the rapid and disturbing spread of extended-spectrum beta-lactamases, AmpC enzymes and quinolone resistance is forcing increased reliance on carbapenems, with resistance to these slowly accumulating via the spread of metallo-, KPC and OXA-48 beta-lactamases. Future options overcoming some of these mechanisms include various novel beta-lactamase-inhibitor combinations, but none of these overcomes all the carbapenemase types now circulating. Multiresistance that includes carbapenems is much commoner in non-fermenters than in the Enterobacteriaceae, depending mostly on OXA carbapenemases in Acinetobacter baumannii and on combinations of chromosomal mutation in Pseudomonas aeruginosa. No agent in advanced development has much to offer here, though there is interest in modified, less-toxic, polymyxin derivatives and in the siderophore monobactam BAL30072, which has impressive activity against A. baumannii and members of the Burkholderia cepacia complex. A final and surprising problem is Neisseria gonorrhoeae, where each good oral agent has been eroded in turn and where there is now little in reserve behind the oral oxyimino cephalosporins, to which low-level resistance is emerging.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Extended-Spectrum β-Lactamases: a Clinical Update
Paterson, D. L., & Bonomo, R. A. (2005) · Clinical Microbiology Reviews · doi:10.1128/cmr.18.4.657-686.2005 · Cited by 3,491
Acinetobacter baumannii : Emergence of a Successful Pathogen
Peleg, A. Y., Seifert, H., & Paterson, D. L. (2008) · Clinical Microbiology Reviews · doi:10.1128/cmr.00058-07 · Cited by 3,316
Carbapenemases: the Versatile β-Lactamases
Queenan, A. M., & Bush, K. (2007) · Clinical Microbiology Reviews · doi:10.1128/cmr.00001-07 · Cited by 2,499
Whitney, C. G., Farley, M. M., Hadler, J., Harrison, L. H., Bennett, N. M., Lynfield, R., Reingold, A., Cieslak, P. R., Pilishvili, T., Jackson, D., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022823 · Cited by 2,228
Spellberg, B., Guidos, R., Gilbert, D., Bradley, J., Boucher, H. W., Scheld, W. M., Bartlett, J. G., Edwards, J., & the Infectious Diseases Society of America (2008) · Clinical Infectious Diseases · doi:10.1086/524891 · Cited by 1,642
High Frequency of Hypermutable Pseudomonas aeruginosa in Cystic Fibrosis Lung Infection
Oliver, A., Cantón, R., Campo, P., Baquero, F., & Blázquez, J. (2000) · Science · doi:10.1126/science.288.5469.1251 · Cited by 1,465
Daptomycin versus Standard Therapy for Bacteremia and Endocarditis Caused by Staphylococcus aureus
Fowler, V. G., Boucher, H. W., Corey, G. R., Abrutyn, E., Karchmer, A. W., Rupp, M. E., Levine, D. P., Chambers, H. F., Tally, F. P., Vigliani, G. A., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa053783 · Cited by 1,459
Multiple Mechanisms of Antimicrobial Resistance in Pseudomonas aeruginosa: Our Worst Nightmare?
Livermore, D. M. (2002) · Clinical Infectious Diseases · doi:10.1086/338782 · Cited by 1,453
Self-citationCTX-M: changing the face of ESBLs in Europe
Livermore, D. M., Canton, R., Gniadkowski, M., Nordmann, P., Rossolini, G. M., Arlet, G., Ayala, J., Coque, T. M., Kern-Zdanowicz, I., Luzzaro, F., et al. (2006) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkl483 · Cited by 927
Self-citationAntimicrobial resistance in developing countries. Part I: recent trends and current status
Okeke, I. N., Laxminarayan, R., Bhutta, Z. A., Duse, A. G., Jenkins, P., O'Brien, T. F., Pablos-Mendez, A., & Klugman, K. P. (2005) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(05)70189-4 · Cited by 851
Intercontinental emergence of Escherichia coli clone O25:H4-ST131 producing CTX-M-15
Nicolas-Chanoine, M.-H., Blanco, J., Leflon-Guibout, V., Demarty, R., Alonso, M. P., Canica, M. M., Park, Y.-J., Lavigne, J.-P., Pitout, J., & Johnson, J. R. (2007) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkm464 · Cited by 821
The role of ISAba1 in expression of OXA carbapenemase genes in Acinetobacter baumannii
Turton, J. F., Ward, M. E., Woodford, N., Kaufmann, M. E., Pike, R., Livermore, D. M., & Pitt, T. L. (2006) · FEMS Microbiology Letters · doi:10.1111/j.1574-6968.2006.00195.x · Cited by 751
Self-citationAntimicrobial resistance in developing countries
Hart, C. A., & Kariuki, S. (1998) · BMJ · doi:10.1136/bmj.317.7159.647 · Cited by 745
Inadequate Antimicrobial Treatment: An Important Determinant of Outcome for Hospitalized Patients
Kollef, M. H. (2000) · Clinical Infectious Diseases · doi:10.1086/314079 · Cited by 635
Schwaber, M. J., & Carmeli, Y. (2007) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkm318 · Cited by 626
Levin, A. S., Barone, A. A., Penço, J., Santos, M. V., Marinho, I. S., Arruda, E. A. G., Manrique, E. I., & Costa, S. F. (1999) · Clinical Infectious Diseases · doi:10.1086/514732 · Cited by 612
Wunderink, R. G., Rello, J., Cammarata, S., et al. (2003) · PubMed · Cited by 566
Landman, D., Georgescu, C., Martin, D. A., & Quale, J. (2008) · Clinical Microbiology Reviews · doi:10.1128/cmr.00006-08 · Cited by 565
Woodford, N., Ward, M. E., Kaufmann, M. E., Turton, J., Fagan, E. J., James, D., Johnson, A. P., Pike, R., Warner, M., Cheasty, T., et al. (2004) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkh424 · Cited by 472
Self-citationWunderink, R. G., Rello, J., Cammarata, S. K., Croos-Dabrera, R. V., & Kollef, M. H. (2003) · Chest · doi:10.1016/s0012-3692(15)33412-7 · Cited by 317
Bratu, S., Tolaney, P., Karumudi, U., Quale, J., Mooty, M., Nichani, S., & Landman, D. (2005) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dki175 · Cited by 307
Prevalence and clonality of extended-spectrum β-lactamases in Asia
Hawkey, P. M. (2008) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2007.01855.x · Cited by 289
Rodriguez-Bano, J., Navarro, M. D., Romero, L., Muniain, M. A., Cueto, M. D., Rios, M. J., Hernandez, J. R., & Pascual, A. (2006) · Clinical Infectious Diseases · doi:10.1086/508877 · Cited by 279
Gales, A. C. (2003) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkg416 · Cited by 242
Impact of conjugate pneumococcal vaccines on antibiotic resistance
Dagan, R., & Klugman, K. P. (2008) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(08)70281-0 · Cited by 239
Acinetobacter radioresistens as a Silent Source of Carbapenem Resistance for Acinetobacter spp
Poirel, L., Figueiredo, S., Cattoir, V., Carattoli, A., & Nordmann, P. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01304-07 · Cited by 205
Lolans, K., Rice, T. W., Munoz-Price, L. S., & Quinn, J. P. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00116-06 · Cited by 202
Coelho, J. M., Turton, J. F., Kaufmann, M. E., Glover, J., Woodford, N., Warner, M., Palepou, M.-F., Pike, R., Pitt, T. L., Patel, B. C., et al. (2006) · Journal of Clinical Microbiology · doi:10.1128/jcm.00699-06 · Cited by 191
Self-citationHenrichfreise, B., Wiegand, I., Pfister, W., & Wiedemann, B. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00148-07 · Cited by 179
Navon-Venezia, S., Leavitt, A., Schwaber, M. J., Rasheed, J. K., Srinivasan, A., Patel, J. B., & Carmeli, Y. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00987-08 · Cited by 170
Threat to Cefixime Treatment for Gonorrhea
Yokoi, S., Deguchi, T., Ozawa, T., Yasuda, M., Ito, S.-I., Kubota, Y., Tamaki, M., & Maeda, S.-I. (2007) · Emerging Infectious Diseases · doi:10.3201/eid1308.060948 · Cited by 162
Cohen, R., Levy, C., de La Rocque, F., Gelbert, N., Wollner, A., Fritzell, B., Bonnet, E., Tetelboum, R., & Varon, E. (2006) · Pediatric Infectious Disease Journal · doi:10.1097/01.inf.0000243163.85163.a8 · Cited by 158
Richter, S. S., Heilmann, K. P., Dohrn, C. L., Riahi, F., Beekmann, S. E., & Doern, G. V. (2008) · Clinical Infectious Diseases · doi:10.1086/595857 · Cited by 146
Turton, J. F., Kaufmann, M. E., Glover, J., et al. (2005) · Journal of Clinical Microbiology · doi:10.1128/jcm.43.7.3074-3082.2005 · Cited by 146
In Vitro and In Vivo Activities of a New Cephalosporin, FR264205, against Pseudomonas aeruginosa
Takeda, S., Nakai, T., Wakai, Y., Ikeda, F., & Hatano, K. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00860-06 · Cited by 140
Novel Polymyxin Derivatives Carrying Only Three Positive Charges Are Effective Antibacterial Agents
Vaara, M., Fox, J., Loidl, G., Siikanen, O., Apajalahti, J., Hansen, F., Frimodt‐Møller, N., Nagai, J., Takano, M., & Vaara, T. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00405-08 · Cited by 138
Bratu, S., Brooks, S., Burney, S. N., Kochar, S., Gupta, J., Landman, D., & Quale, J. M. (2007) · Clinical Infectious Diseases · doi:10.1086/512370 · Cited by 122
Livermore, D. M., Mushtaq, S., Warner, M., Miossec, C., & Woodford, N. (2008) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkn320 · Cited by 120
Self-citationEmergence and spread of azithromycin-resistant Neisseria gonorrhoeae in Scotland
Palmer, H. M., Young, H.-K., Winter, A., & Dave, J. (2008) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkn235 · Cited by 117
Non-susceptibility trends among staphylococci from bacteraemias in the UK and Ireland, 2001-06
Hope, R., Livermore, D. M., Brick, G., Lillie, M., Reynolds, R., & Surveillance, O. B. O. T. B. W. P. O. R. (2008) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkn353 · Cited by 117
Self-citationNon-susceptibility trends among Enterobacteriaceae from bacteraemias in the UK and Ireland, 2001-06
Livermore, D. M., Hope, R., Brick, G., Lillie, M., Reynolds, R., & Surveillance, O. B. O. T. B. W. P. O. R. (2008) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkn351 · Cited by 102
Self-citationIntroduction: the challenge of multiresistance
Livermore, D. M. (2007) · International Journal of Antimicrobial Agents · doi:10.1016/s0924-8579(07)00158-6 · Cited by 75
Self-citationRe-emergence of colistin in today's world of multidrug-resistant organisms: personal perspectives
Falagas, M. E., & Rafailidis, P. I. (2008) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.17.7.973 · Cited by 70
Orthodox and unorthodox clavulanate combinations against extended-spectrum β-lactamase producers
Livermore, D. M., Hope, R., Mushtaq, S., & Warner, M. (2008) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2007.01858.x · Cited by 70
Self-citationBrown, D. F., Hope, R., Livermore, D. M., Brick, G., Broughton, K., George, R. C., Reynolds, R., & Surveillance, O. B. O. T. B. W. P. O. R. (2008) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkn354 · Cited by 61
Self-citationMuder, R. R., Cunningham, C. A., McCray, E. E., Squier, C. L., Perreiah, P. L., Jain, R., Sinkowitz‐Cochran, R. L., & Jernigan, J. A. (2008) · Infection Control and Hospital Epidemiology · doi:10.1086/589981 · Cited by 58
Aschbacher, R., Doumith, M., Livermore, D. M., Larcher, C., & Woodford, N. (2008) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkm508 · Cited by 55
Self-citationHikida, M., Itahashi, K., Igarashi, A., Shiba, T., & Kitamura, M. (1999) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.43.8.2010 · Cited by 52
Future directions with daptomycin
Livermore, D. M. (2008) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkn371 · Cited by 45
Self-citationUptake of a catecholic cephalosporin by the iron transport system of Escherichia coli
Critchley, I. A., BASKER, M. J., Edmondson, R. A., & KNOTT, S. J. (1991) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/28.3.377 · Cited by 21
Kihara, R., Yanagihara, K., Morinaga, Y., Araki, N., Nakamura, S., Seki, M., Izumikawa, K., Kakeya, H., Yamamoto, Y., Tsukamoto, K., et al. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01532-07 · Cited by 19
Current challenges in treating MRSA: what are the options?
Ratnaraja, N., & Hawkey, P. M. (2008) · Expert Review of Anti-infective Therapy · doi:10.1586/14787210.6.5.601 · Cited by 17
C difficile cases rising, but MRSA rates falling
Eaton, L. (2007) · BMJ · doi:10.1136/bmj.39288.642593.db · Cited by 6
Cited by
Kumarasamy, K. K., Toleman, M. A., Walsh, T. R., Bagaria, J., Butt, F., Balakrishnan, R., Chaudhary, U., Doumith, M., Giske, C. G., Irfan, S., et al. (2010) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(10)70143-2 · Cited by 2,922
Self-citationAntibiotic resistance is ancient
D’Costa, V. M., King, C. E., Kalan, L., Morar, M., Sung, W. W. L., Schwarz, C., Froese, D., Zazula, G., Calmels, F., Debruyne, R., et al. (2011) · Nature · doi:10.1038/nature10388 · Cited by 2,720
Antibiotics and Bacterial Resistance in the 21st Century
Fair, R. J., & Tor, Y. (2014) · Perspectives in Medicinal Chemistry · doi:10.4137/pmc.s14459 · Cited by 1,955
Walsh, T. R., Weeks, J., Livermore, D. M., & Toleman, M. A. (2011) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(11)70059-7 · Cited by 1,250
Self-citationEnvironmental factors influencing the development and spread of antibiotic resistance
Bengtsson-Palme, J., Kristiansson, E., & Larsson, D. G. J. (2018) · FEMS Microbiology Reviews · doi:10.1093/femsre/fux053 · Cited by 1,167
Metadata
- Authors
- Livermore, D. M.
- Venue
- Journal of Antimicrobial Chemotherapy
- Publisher
- Oxford University Press (OUP)
- Published
- 2009-08-12
- Volume
- 64
- Issue
- Supplement 1
- Pages
- i29-i36
- ISSN
- 0305-7453 (ISSN-L)
- 1460-2091
- OpenAlex
- W2153732335
- Cited by
- 620
- References
- 53
- FWCI
- 27.02
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.